Oxaliplatin-Induced Immune-Mediated Thrombocytopenia: A Case Report / Journal of the Korean Cancer Association, 대한암학회지
Cancer Research and Treatment
;
: 949-953, 2015.
Article
in English
| WPRIM
| ID: wpr-90542
ABSTRACT
Oxaliplatin is a third-generation platinum derivative used for metastatic or advanced colorectal cancer treatment. Although myelosuppression is the most common cause of oxaliplatin-induced thrombocytopenia, rare cases of oxaliplatin-induced immune-mediated thrombocytopenia are reported. We report a case of a 57-year-old woman with colon cancer who developed gum bleeding and petechiae after oxaliplatin infusion. Laboratory tests revealed grade 4 thrombocytopenia and grade 4 neutropenia. She recovered from the thrombocytopenia and accompanying neutropenia within 4 days with no recurrence following discontinuation of oxaliplatin. Physicians need to be aware of the risk of severe acute thrombocytopenia following oxaliplatin administration.
Full text:
Available
Index:
WPRIM (Western Pacific)
Main subject:
Platinum
/
Purpura
/
Recurrence
/
Thrombocytopenia
/
Colorectal Neoplasms
/
Colonic Neoplasms
/
Gingiva
/
Hemorrhage
/
Neutropenia
Limits:
Female
/
Humans
Language:
English
Journal:
Cancer Research and Treatment
Year:
2015
Type:
Article
Similar
MEDLINE
...
LILACS
LIS